Solutions in the Search for Lower-Cost, Smart Pharmaceuticals

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

We all know health care costs in the United States are absurdly high. As a percentage of GDP, our health care spending is more than 50% greater than the runner-up, Germany. Over recent years, the growth rate in health care spending has been double the growth of the overall economy, yet societal wellbeing continues to decline.

Perhaps most stunningly of all, for those who face a major health crisis or chronic disease, it is all too common to see expenses that stack up into hundreds of thousands of dollars or even bankrupt families completely. This is not just sad, it’s unacceptable.

As a pharmacist with a background in pharmacological research, I’m familiar with one major engine behind that trend: a move toward increasingly complex and sexy-sounding novel drugs and treatments used to justify these high costs. But amidst this frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Obviously, patients should receive treatments that have been clinically proven, and physicians are obligated to recommend or prescribe things that are supported by data. What we’re missing is the research and investment in cost-cutting models: companies that research and produce low-cost medicines and try to make treatments simpler and more efficient.

When affordability aligns with safety and convenience

Recently I wrote about the shift in research on inflammatory disease, from classic, time-tested non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines to biologics. Biologics are a new category of medicines with fascinating potential, but as I pointed out, they are complex to manufacture and administer.

They require injections or infusions, they break down easily, and, therefore, have special storage and shipment requirements. Further, they often cost hundreds to thousands of dollars per dose, which are costs that are passed on to patients or through insurance companies to the public at large. Big pharma companies are incredibly proud of these highly sophisticated, “sexier” solutions.

But are they also the smartest solution, truly? To delve further into that topic, consider this example. Say you have rheumatoid arthritis, one of the more common autoimmune diseases. If you’re young, one treatment a doctor might recommend is an NSAID—they are, in fact, often effective at managing inflammation even for serious conditions.

But if you try an NSAID and your symptoms break through, or you have gastrointestinal adverse effects (AEs) from the NSAID, your physician probably won’t want to drag you through a long process of trying different NSAIDs to find a better match. There’s no one really working to optimize NSAIDs, so patients end up jumping to a different class of drugs altogether.

The next option under the current regime is methotrexate, a very powerful drug also used for chemotherapy. Methotrexate can initially be effective, but it can cause a lot of AEs and put you in this scary category of being immunocompromised, which is even more unsettling word for people in the age of COVID-19.

Then, if methotrexate alone isn’t enough to control the disease long term, the next option is adding a novel treatment, such as an injectable biologic drug, which can cost thousands of dollars per treatment. Is that really the best protocol for patients?

There are more than 2 dozen NSAIDs, most of which are off-patent, and dozens of different antihistamines that are all related to the core problem: inflammation. Additionally, there is strong evidence that some antihistamines can help block the gastrointestinal AEs of NSAIDs, making them more feasible to take regularly. Many of these drugs may be superior in their efficacy, AE profile, and convenience—requiring just a daily pill—compared to the expensive newer drugs.

But until someone steps forward to do the research, find the best combination and dosage, prove it works, and develop a concise, well-packaged product, physicians and patients are stuck with their limited toolkit.

Stepping away from rheumatoid arthritis, there are many cases in which I think NSAIDs and antihistamines in the right combination will prove advantageous for many people, and I’ve already seen some evidence to back it up. Those situations include treating the inflammatory symptoms of COVID-19, managing chronic pain without the risk of addiction, helping people cope with opioid withdrawal, and even avoid hangovers. And scientific researchers, worldwide are starting to agree with me.

David vs. Goliath

Big pharmaceutical companies are entrenched in their model, spending hundreds of millions finding new drugs or buying patents from small companies that can’t fund a full clinical study on their own. When a new drug hits the market, pharmaceutical companies argue the big price tag to patients and insurers which is necessary to recoup those extensive research costs. And maybe their shareholders are behind these escalations as well.

The fact is, it’s much less expensive to develop new and exciting treatment regimens studying known drugs. Their safety is established, we know they work, and we can look over existing data and find fascinating connections, such as when those taking the medications long term have lower rates of other symptoms and diseases. It’s relatively straight forward to test it when you already see it working. Those savings, in turn, can be passed on to consumers, creating a better market for everyone.

Do well by doing good

There are people who think a pharmaceutical company with a mission of charging less for drugs is a surprising act of altruism. What it really is, I think, is a chance for people to align their ideals with good business, because there is certainly a vast market for these options.

At the same time, policymakers and philanthropists who are looking for ways to reel in the exorbitant price of treatments ought to think of this as one of the ways to get there—a path of least resistance. Instead of fighting industry to control costs, invest in affordable options. And in the meantime, develop new pharmaceutical options that are safe, convenient, empirically sound, and improve quality of life. Now that’s what I call win-win.

About the Author

Jackie Iversen, RPh, MS, founder and head of Clinical Development Sen-Jam Pharmaceutical.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.